Print Page  Close Window

Investor Relations
Corporate Profile

We are Zogenix.

Zogenix is committed to developing therapies that address specific clinical needs for people living with CNS and pain-related conditions who need innovative treatment alternatives to help them return to normal daily functioning.

A significant number of patients are not being effectively treated, despite the availability of current therapies. These patients deserve access to safe and effective treatments. Zogenix is committed to ensuring the safe and appropriate use of our products ... More >>

Latest PresentationsMore >>
Title
Download Documentation Zogenix February 2015 Investor Presentation
Get help downloading or viewing the above file types
Stock Quote
ZGNX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$1.68
Change (%) Stock is Up 0.01 (0.60%)
Volume2,246,234
Data as of 03/04/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
03/02/15Zogenix Announces Conference Call and Webcast to Present Fourth Quarter and Full Year 2014 Financial Results
Conference Call Scheduled for March 10, 2015 at 4:30 pm ET SAN DIEGO, March 2, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, today announced it will release financial results for the fourth quarter and full year ended December 31, 2014, after the market closes on Tuesday, March 10, 2015, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), ... 
Printer Friendly Version
02/10/15Zogenix Appoints Industry Veteran Renee Tannenbaum to Its Board of Directors
SAN DIEGO, Feb. 10, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, announced today that Renee Tannenbaum, Pharm.D., has been appointed as a new member of the Company's Board of Directors. Cam L. Garner, Chairman of the Board, said, "Dr. Tannenbaum has significant experience developing and executing commercial strategies in the pharmaceutical industry. Her stron... 
Printer Friendly Version
02/05/15Zogenix to Participate in Leerink Global Healthcare Conference
SAN DIEGO, Feb. 5, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, today announced that Ann Rhoads, Chief Financial Officer, will present at the Leerink Global Healthcare Conference in New York, NY on February 11, 2015. Ms. Rhoads will participate in a fireside chat presentation and provide a general company update. Event: Leerink Global ... 
Printer Friendly Version
01/30/15Zogenix Receives FDA Approval of New Formulation of Zohydro(R) ER
Zohydro ER With BeadTek(TM) to be Available in the Second Quarter of 2015 SAN DIEGO, Jan. 30, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has approved a new formulation of Zohydro® ER (hydrocodone bitartrate) Extended-Release Capsules, CII, with BeadTek™. BeadTek is a formulation technology design... 
Printer Friendly Version
Upcoming EventsMore >>
DateTitle
03/10/15 4:30 p.m. ET
Q4 2014 Zogenix, Inc. Earnings Conference Call

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.